| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Jul―21 |
0625 Skin as a potential entry point for SARS-CoV-2 virus |
I.V. Budunova, D. Trubetskoy, P. Grudzien, A. Klopot, D. Chudakova, B. Shi, P. Bhalla, B. E. Perez White |
| 2 |
[GO] |
2025―Jul―21 |
1018 Cutaneous STING pathway agonism enhances the immunogenicity of a SARS-CoV-2 ferritin nanoparticle vaccine in both young and aged mice |
S. Singh, S. Balmert, S. Mahendiratta, C.D. Carey, A. Dhayani, J. Zhang, A. Hajduczki, W.C. Chang, P.A. Rees, M.G. Joyce, E. Korkmaz, L.D. Falo |
| 3 |
[GO] |
2025―Jul―21 |
0287 Assessing the risk of pediatric alopecia areata after COVID-19 infection: A population-level study |
E. Weisert, L. Hamilton, A.R. Jimenez, M.G. Wilkerson |
| 4 |
[GO] |
2025―Jul―21 |
0252 Insights from a veteran cohort: Does tumor necrosis factor-alpha (TNF-α) inhibitor use impact COVID-19 breakthrough infection risk in vaccinated dermatology patients? |
J. Breunig, J. Cheng, L. Romero |
| 5 |
[GO] |
2025―Jul―21 |
LB1068 Increasing concern over the cost of facial cosmetic dermatological procedures since the onset of COVID-19 |
V.A. Pecora, T. Erguven, S. Sharifi, K. Nouri, A. Landriscina |
| 6 |
[GO] |
2025―Mar―17 |
57: Impact of pediatric teledermatology on historically underserved patients during COVID-19 pandemic compared to pre-COVID year in the Pacific Northwest |
Danielle McClanahan, Milie Fang, Tracy Funk, Jeong Youn Lim, Emile Latour, Julie Dhossche |
| 7 |
[GO] |
2024―Dec―24 |
Correlation between Androgentic Alopecia and SARS-CoV-2 Omicron variant infection in China |
Shuying Lv, Xiaohui Zou, Lei Wang, Yonglong Xu, Chuhan Huang, Shiyi Zhong, Wenjun Lin, Ying Xie, Huijuan Fang, Meijiao Du, Yunran Cui, Ruiying Wu, Yuqi Jiang, Mingyue Zhuang, Jieping Huang, Dingquan Yang |
| 8 |
[GO] |
2024―Dec―10 |
From Viral Infection to Skin Affliction: Unveiling Mechanisms of Cutaneous Manifestations in COVID-19 and Post-COVID Conditions |
Nesrine Brahimi, David Croitoru, Fanny Saidoune, Haleh Zabihi, Michel Gilliet, Vincent Piguet |
| 9 |
[GO] |
2024―Nov―20 |
075 COVID-19 vaccination is associated with decreased risk for pemphigus and pemphigoid while COVID-19 infection elevates the risk: A global population-based cohort study |
P. Curman, R. Ludwig |
| 10 |
[GO] |
2024―Jul―19 |
111 The number needed to biopsy for cutaneous melanoma in residency clinics during the COVID-19 era |
J. Kibbie, S. Zita, C. Armstrong |
| 11 |
[GO] |
2024―Jul―19 |
247 Biologics protect psoriasis patients from being exacerbated by COVID-19 infection |
Y. Zheng, X. Chen |
| 12 |
[GO] |
2024―Jul―19 |
117 A cross-sectional analysis of photodynamic therapy use and medicare expenditures amongst dermatologists before and during the COVID-19 pandemic |
S. Neman, N. Ugwu, J. Trinidad |
| 13 |
[GO] |
2024―Jul―19 |
206 Non-evidence based use of hydroxychloroquine during the COVID-19 pandemic and spike in reports of pemphigus; A disproportionality analysis of the FDA adverse event reporting system (FAERS) |
J. Baroukhian, K. Seiffert-Sinha, A.A. Sinha |
| 14 |
[GO] |
2024―Jul―19 |
540 Covid-19-related alterations in racial disparities in dermatology practice patterns |
S. Cui, L. Zhang, Y. Xie, B. Pentland, A.P. Pentland, J. Ryan Wolf |
| 15 |
[GO] |
2024―Feb―21 |
Autophagy during Severe Acute Respiratory Syndrome Coronavirus 2 Induced Leukocytoclastic Vasculitis: New Insights |
Nesrine Brahimi, Vincent Piguet |
| 16 |
[GO] |
2023―Nov―06 |
3 Hand-foot-vulva pustule After COVID-19 inactive vaccine |
Y. Xie, B. Yin |
| 17 |
[GO] |
2023―Nov―06 |
245 A rare case of erythrodermic sarcoidosis with systemic involvement after COVID-19 vaccination |
B. Lapolla, E. Gordon, O. Adeuyan, C. Schreidah, L. Fahmy, C. Magro, L. Geskin |
| 18 |
[GO] |
2023―Nov―06 |
49 A pink nodule developed after COVID-19 vaccine |
C. Li, Y. Feng |
| 19 |
[GO] |
2023―Nov―06 |
17 New-onset bullous pemphigoid after SARS-CoV-2 infection |
S. Zhoi |
| 20 |
[GO] |
2023―Aug―12 |
SARS-CoV-2 induced vasculitic skin lesions are associated with massive spike protein depositions in autophagosomes |
Andrea Gawaz, Michael Schindler, Elena Hagelauer, Gabriela Blanchard, Simon Riel, Anneli Vollert, Michel Gilliet, Luisa Unterluggauer, Georg Stary, Isabella Pospischil, Wolfram Hoetzenecker, Birgit Fehrenbacher, Martin Schaller, Emmanuella Guenova, Stephan Forchhammer |
| 21 |
[GO] |
2023―Apr―17 |
691 Visualization of Covid-19 pandemic influence on healthcare routines in dermatology using electronic health record data |
J. Ryan Wolf, L. Zhang, Y. Xie, A. Pentland, B.T. Pentland |
| 22 |
[GO] |
2023―Apr―17 |
576 Gender disparities in isotretinoin prescribing patterns for pediatric patients before and during the COVID-19 pandemic |
A.J. Tan, J. Xia, D. Kroshinsky |
| 23 |
[GO] |
2023―Apr―17 |
453 Limited effect of reducing pulmonary tuberculosis incidence amid mandatory facial masking for COVID-19 |
E. Lin, H. Tu, C. Hong |
| 24 |
[GO] |
2023―Apr―17 |
403 Updated findings from the Global HS COVID-19 Registry |
H. Naik, R. Alhusayen, S. Guilbault, J. Ingram, M. Lowes, A. Marzano, B. Villumsen, C. Yannuzzi |
| 25 |
[GO] |
2023―Apr―17 |
228 Impact of COVID-19 and PPE measures on occupational skin disease in healthcare workers |
S. Chawla, M. Chawla, M. Fugger, C. Moore-gillon, R. Watchorn |
| 26 |
[GO] |
2023―Apr―17 |
227 Immune response and allergenic components of COVID-19 vaccines induced delayed cutaneous reactions |
C. Tsai, W. Chung, C. Chen |
| 27 |
[GO] |
2023―Apr―17 |
226 Characteristics of immune response profile in patients with immediate allergic and autoimmune urticarial reactions induced by COVID-19 vaccines |
C. Wang, C. Chen, W. Chung |
| 28 |
[GO] |
2023―Apr―17 |
222 Severe COVID-19 infection predisposes patients to greater burden of hair loss |
S. Patel, M. Colavincenzo |
| 29 |
[GO] |
2023―Apr―17 |
224 Humoral immune response to COVID-19 vaccination in psoriasis patients on biologic therapy is impaired compared to healthy controls |
H. Puschmann, W. Milz, S. Emmert, R. Panzer |
| 30 |
[GO] |
2023―Apr―17 |
223 Spectrum changes of pediatric dermatological disorders before and during the COVID-19 pandemic in China: A single national center for children’s health experience |
Y. Liu, L. Ma |
| 31 |
[GO] |
2023―Apr―17 |
221 Impact of the COVID-19 surge on phototherapy in Taiwan: Experience from a university hospital |
C.E. Lan, K. Chu |
| 32 |
[GO] |
2023―Apr―17 |
220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains |
M. Tihy, S. Matar, P. Sohier, N. Dupin, S. Aractingi, B. Oulès |
| 33 |
[GO] |
2023―Apr―17 |
156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset |
A. Pira, F. Mariotti, F. Moro, A. Panebianco, S. Pallotta, B. Didona, G. Di Zenzo |
| 34 |
[GO] |
2023―Apr―17 |
219 Clinical and immunological impact of booster immunization with recombinant mRNA vaccines for SARS-CoV-2 in patients with pemphigus and bullous pemphigoid |
A. Mesas Fernández, F. Solimani, E. Bodner, M. Carevic-Neri, T. Jakovljevicova, A. Philipp, A. Nast, M. Worm, F. Hilke, K. Meier, K. Ghoreschi |
| 35 |
[GO] |
2023―Apr―17 |
225 Enhanced TLR7 immunity drives innate protection against SARS-CoV-2 with chilblains as collateral damage. |
A. Yatim, F. Saidoune, J. Di Domizio, R. Jenelten, A. Joncic, M. Morren, C. Conrad, J. Casanova, M. Gilliet |
| 36 |
[GO] |
2023―Apr―01 |
T Cells Remember SARS-CoV-2 in Rituximab-Treated Pemphigus Vulgaris |
David O. Croitoru, Vincent Piguet |
| 37 |
[GO] |
2023―Jan―28 |
SARS-CoV-2 vaccination effectiveness in Rituximab-treated patients affected by Pemphigus Vulgaris |
C. Fenizia, C. Moltrasio, L. Ottobrini, O. Utyro, G. Genovese, C. Vanetti, D. Trabattoni, A.V. Marzano |
| 38 |
[GO] |
2022―Nov―18 |
076 Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries |
P Study Group, G. Rheumatology Alliance Study Group |
| 39 |
[GO] |
2022―Nov―18 |
160 Selected psychological stress and cognitive function parameters in patients suffering from COVID-19 induced telogen effluvium |
K. Tomaszewska, J. Lawniczak, B. Tarkowski, J. Dudek, A. Zalewska-Janowska |
| 40 |
[GO] |
2022―Nov―18 |
063 Autoimmunity and disease outcomes of COVID-19, lessons from vitiligo patients |
N. Post, M. Bekkenk, R. Luiten |
| 41 |
[GO] |
2022―Nov―18 |
073 Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform |
S. Langan, C. Smith, T. Collaborative |
| 42 |
[GO] |
2022―Nov―18 |
147 Cutaneous Manifestations on Covid-19 Patients: A Systematic Review |
M. Trifitriana, R. Mulawarman |
| 43 |
[GO] |
2022―Nov―18 |
369 Single-cell RNA sequencing analysis of a COVID-19-associated maculopapular rash in a psoriasis patient treated with ustekinumab |
K. Rindler, M. Drach, L. Shaw, W. Weninger, M. Farlik, C. Jonak, P.M. Brunner |
| 44 |
[GO] |
2022―Nov―18 |
168 New considerations regarding vesicular rashes associated with SARS-CoV2 infection and Koebner phenomenon |
A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, E.B. Niculet, L.C. Nwabudike, D. Radaschin |
| 45 |
[GO] |
2022―Aug―24 |
Monkeypox: Considerations as a New Pandemic Looms |
Matthew G. Brewer, Stephanie R. Monticelli, Brian M. Ward |
| 46 |
[GO] |
2022―Jul―20 |
205 COVID-19 complications in vitiligo patients: A multicenter study |
R. Raiker, S. Salingaros, H. Pakhchanian, M. Helm |
| 47 |
[GO] |
2022―Jul―20 |
267 Impact of COVID-19 healthcare disruption on delays in melanoma treatment in rural and urban Iowa |
A. Munjal, M. Fitzhugh, M. Walsh, P. Gorrepati, R. Tripathi, V. Liu, J.G. Powers |
| 48 |
[GO] |
2022―Jul―20 |
157 Severity of COVID-19 in patients with dermatomyositis: A single center, retrospective observational cohort study |
J.S. Johnson, A. Nowacki, J. Narang, S. Young, A. Fernandez |
| 49 |
[GO] |
2022―Jul―20 |
160 Halved incidence of scrub typhus after travel restriction to confine a surge of COVID-19 in Taiwan in 2021 |
E. Lin, H. Tu, C. Hong |
| 50 |
[GO] |
2022―Jul―20 |
LB897 The risk of COVID-19 infection in patients with alopecia areata |
A. Oulee, S. Ahn, S. Shahsavari, A. Martin, J.J. Wu |
| 51 |
[GO] |
2022―Jul―20 |
270 Impact of COVID-19 infection on hidradenitis suppurativa activity |
M.E. Torpey, A. Nosrati, K.L. Campton, S.R. Cohen |
| 52 |
[GO] |
2022―Jul―20 |
168 COVID-19 mRNA vaccine booster cutaneous reactions reported to the AAD/ILDS dermatology registry |
S. Prasad, D.E. McMahon, A. Tyagi, R. Singh, R. Ali, H.W. Lim, L.P. Fox, K. Blumenthal, G. Hruza, L.E. French, E. Freeman |
| 53 |
[GO] |
2022―Jul―20 |
173 Analyzing the impact of COVID-19 on trends in the dermatology literature |
R. Ali, S. Prasad, R. Singh, L. Abdelrahman, R. Kankaria, S. Singh, S. Mehta, V. Mroz, E. Freeman |
| 54 |
[GO] |
2022―Jul―20 |
395 Utilization of teledermatology services for dermatological diagnoses during the COVID-19 pandemic |
A. He, T.T. Kim, K. Nguyen |
| 55 |
[GO] |
2022―Jul―20 |
387 Consumer attitudes, knowledge, and behavior towards aging skin during the COVID-19 pandemic |
L. Yang, J. Knoll, R.V. Kundu |
| 56 |
[GO] |
2022―Jul―20 |
357 Skin cancer treatment delays during the COVID-19 pandemic |
C.B. Lau, K. Yang, C.X. Pan, W.C. Lau, B. Kassamali, V. Nambudiri |
| 57 |
[GO] |
2022―Jul―20 |
347 Patient interest in Mohs surgery telehealth services beyond the COVID-19 pandemic |
A. Munjal, R. Tripathi |
| 58 |
[GO] |
2022―Jul―20 |
384 Impact of the COVID-19 pandemic on dermatology visits among older adults and racial and ethnic minorities |
N. Rizk, M.B. Mathur, J. Ko, A. Chiou, I. de Vere Hunt, S. van Egmond, E. Linos |
| 59 |
[GO] |
2022―Jul―20 |
LB1032 Influence of the covid-19 pandemic on emergency room usage for dermatologic ailments |
S. Gotewal, A. Good, M. Wilkerson |
| 60 |
[GO] |
2022―Jul―20 |
LB955 Adherence in dermatology during the COVID-19 pandemic: A review |
S.G. Bridgeman, P.O. Perche, S.R. Feldman |
| 61 |
[GO] |
2022―Jul―20 |
145 Erythema multiforme in COVID-19 patients and following COVID-19 vaccination |
F. Etaee, M. Basiri, T. Naguib, S. Daveluy |
| 62 |
[GO] |
2022―Jul―20 |
422 Keratinocyte media differences uncovered during COVID-19 supply shortages |
E.M. Pope, M.C. Moran, M.G. Brewer, L.A. Beck |
| 63 |
[GO] |
2022―Jul―20 |
359 Public sunscreen dispenser distribution in the United States: Continued COVID-19 trends during 2021 |
M.D. Szeto, R. Kokoska, J. Maghfour, C. Rundle, C. Presley, T. Harp, A. Hamp, V. Wegener, J. Hugh, R. Dellavalle |
| 64 |
[GO] |
2022―Jul―20 |
366 Comparing patient perspectives towards treatment for alopecia areata before and during COVID-19 using social media data mining |
J. Jueng, V. Bhupalam, A. Su, C.M. Infante, L. Dupuis, S. Shaikh, R. Dellavalle, I. Brooks, O. Burton, J. Solomon |
| 65 |
[GO] |
2022―Jul―20 |
265 Evaluating the safety and effectiveness of the COVID-19 vaccination among pediatric atopic dermatitis patients |
H. Pakhchanian, R. Raiker, K. Jenkins, L. Shen |
| 66 |
[GO] |
2022―Jul―20 |
260 Responses following COVID-19 vaccination in patients with autoimmune skin disease |
G. Sprow, M. Afarideh, J. Dan, E. Keyes, M. Grinnell, J. Concha, T. Vazquez, D. Diaz, N. Kodali, V. Werth |
| 67 |
[GO] |
2022―Jul―20 |
262 Safety and efficacy of the COVID-19 vaccine among fully vaccinated and boosted skin cancer patients |
R. Raiker, H. Pakhchanian, M. Deng |
| 68 |
[GO] |
2022―Jul―20 |
149 Proposing a standardized assessment of COVID-19 vaccine cutaneous reactions |
R. Singh, R. Ali, S. Prasad, K. Blumenthal, E. Freeman |
| 69 |
[GO] |
2022―Jul―20 |
LB926 COVID-19 vaccine hesitancy in a cohort of hidradenitis suppurativa patients |
M. Torpey, A. Nosrati, K.L. Campton, S. Cohen |
| 70 |
[GO] |
2022―Jul―20 |
LB923 COVID-19 vaccine immunity in hidradenitis suppurativa patients receiving TNF-alpha inhibitors |
A. Nosrati, M.E. Torpey, G.D. Ball, N. Shokrian, K.L. Campton, S.R. Cohen |
| 71 |
[GO] |
2022―Jul―20 |
322 Is social media spreading misinformation on the COVID-19 vaccines within the psoriasis community? |
D. Yee, C. Zagona-Prizio, S. Khan, S. Khan, N. Maynard, M.D. Mehta, R. Reddy, A.W. Armstrong |
| 72 |
[GO] |
2022―Jul―20 |
LB1043 COVID-19-associated pruritus is non-histaminergic mediated |
A. Labib, L.A. Nattkemper, A. Vander Does, T. Ju, S. Cacciapuoti, M. Vastarella, G. Fabbrocini, G. Yosipovitch |
| 73 |
[GO] |
2022―Jul―20 |
801 Experience of advanced dermatology and cosmetic surgery clinics providers with teledermatology amidst the coronavirus disease-19 lockdown |
C.M. Infante, J. Jueng, A. Su, B. Maner, T. Harding, S. Eubanks, J. Solomon |
| 74 |
[GO] |
2022―Jul―20 |
LB981 Pandemic associated chilblain-like lesions result from an inducible type 1 interferon response to SARS-CoV-2 |
L. Arkin, A. Costa da Silva, J. Mays |
| 75 |
[GO] |
2022―Jul―20 |
850 Potential role of skin in SARS-CoV-2 infection |
D. Chudakova, A. Klopot, B. Shi, P. Bhalla, L.C. Tsoi, B.E. Perez White, I. Budunova |
| 76 |
[GO] |
2022―Jul―20 |
389 Impact of the COVID19 pandemic on the execution of real world, pragmatic trials: The LITE study experience |
B. Hefele, K. Duffin, L. Howard, D.B. Shin, J.M. Gelfand |
| 77 |
[GO] |
2021―Oct―08 |
067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases |
T. Hillary, A. Van Laethem, F. Castelijns, S. Vermeire, J. Geldof, M. Ferrante, K. De Vlam, P. Verschueren, J. Sabino, T. Lobaton, H. Lapeere, J. Lambert |
| 78 |
[GO] |
2021―Oct―08 |
072 Covid-19 and male androgenetic alopecia: Systematic investigation of a potential epidemiological and genetic association |
S.K. Henne, L.M. Hochfeld, C. Maj, M.M. Nöthen, S. Heilmann-Heimbach |
| 79 |
[GO] |
2021―Oct―08 |
065 Application of teledermatology during the first wave of the COVID-19 pandemic in Hungary |
A. Jobbágy, F. Meznerics, K. Farkas, S. Bozsányi, L. Fesus, N. Kiss, K. Lorincz, N. Wikonkal, M. Sárdy, A. Bánvölgyi |
| 80 |
[GO] |
2021―Oct―08 |
055 The impact of methotrexate and targeted immunosuppression on cellular and humoral immune responses to COVID-19 vaccine BNT162b2: a cohort study |
S.K. Mahil, K. Bechman, A. Raharja, C. Domingo-Vila, M. Brown, A. Cope, M. Malim, E. Pollock, J. Seow, J. Barker, S. Norton, J. Galloway, K. Doores, T. Tree, C. Smith |
| 81 |
[GO] |
2021―Oct―08 |
245 Demodex folliculorum interaction with SARS-CoV2 from a chitin-lipid perspective |
A.L. Tatu, T. Nadasdy, F.C. Bujoreanu, D. Radaschin, L.C. Nwabudike |
| 82 |
[GO] |
2021―Aug―19 |
LB761 Clinical outcomes in Pemphigoid and Pemphigus patients with COVID-19 |
H. Pakhchanian, R. Raiker, J. Wang, K. Phan |
| 83 |
[GO] |
2021―Aug―19 |
LB751 COVID-19 complications in patients with Hidradenitis Suppurativa: A multicenter study |
R. Raiker, H. Pakhchanian, K. Phan |
| 84 |
[GO] |
2021―Aug―19 |
LB767 A multicenter analysis of patients using telemedicine for dermatological conditions during the COVID-19 pandemic |
R. Raiker, H. Pakhchanian, M. Baker, E. Hochman, M. Deng |
| 85 |
[GO] |
2021―Aug―19 |
LB723 Face skin changes caused by face mask during the COVID-19 pandemic |
S. Park, J. Han, Y. Yeong, N. Kang, B. SUH, E. Kim |
| 86 |
[GO] |
2021―Aug―19 |
LB768 Adult and pediatric emergency department visits for dermatological conditions during the COVID-19 pandemic: A multicenter analysis |
H. Pakhchanian, R. Raiker, K. Russomanno, M. Deng |
| 87 |
[GO] |
2021―Aug―19 |
LB771 Racial and Ethnic Disparities in COVID-19-Related Infection in Patients with Psoriasis: A Cross-Sectional Study |
C. Nguyen, S. Shwe, K. Yale, A. Ghigi, K. Zheng, N. Mesinkovska, T. Bhutani |
| 88 |
[GO] |
2021―Aug―19 |
LB740 SARS-CoV-2-associated ‘covid toes:’ multiplex immunofluorescent characterization of pathophysiology |
J.J. Moon, A. Costa da Silva, J.M. Tran, C. Kim, R. Sharma, M. Hinshaw, B.E. Shields, E. Brooks, E.W. Cowen, A. Singh, B. Drolet, J. Mays, L. Arkin |
| 89 |
[GO] |
2021―Aug―04 |
Assessing the risk and outcome of COVID-19 in patients with psoriasis or psoriatic arthritis on biologic treatment: a critical appraisal of the quality of the published evidence |
Stefano Piaserico, Paolo Gisondi, Simone Cazzaniga, Sara Di Leo, Luigi Naldi |
| 90 |
[GO] |
2021―Jul―15 |
From your nose to your toes: A Review of SARS-CoV-2 Pandemic-associated Pernio |
Lisa M. Arkin, John J. Moon, Jennifer M. Tran, Samira Asgari, Cliona O’Farrelly, Jean-Laurent Casanova, Edward W. Cowen, Jacqueline W. Mays, Anne Marie Singh, Beth A. Drolet |
| 91 |
[GO] |
2021―Apr―19 |
255 The risk of contracting COVID-19 after dermatological procedures compared with other medical procedures |
R. Raiker, H. Pakhchanian, A. Baghdjian, V.A. Patel |
| 92 |
[GO] |
2021―Apr―19 |
336 Risks of COVID-19 infection and mortality for patients on biologics |
V. Pahalyants, W. Murphy, N. Klebanov, N. Theodosakis, M. Klevens, E. Lilly, M. Asgari, Y. Semenov |
| 93 |
[GO] |
2021―Apr―19 |
028 Use of systemic immunosuppressive treatment is not related to COVID-19 infection in a retrospective review of patients in Massachusetts |
W. Murphy, N. Klebanov, V. Pahalyants, N. Theodosakis, K. Patel, M. Klevens, E. Lilly, Y. Semenov |
| 94 |
[GO] |
2021―Apr―19 |
316 The impact of COVID-19 on gender representation in academic dermatology publications |
M.D. Szeto, M. Laughter, M.B. Maymone, T.E. Sivesind, C.L. Presley, S.M. Lada, K.J. Pulsipher, R. Dellavalle |
| 95 |
[GO] |
2021―Apr―19 |
652 Using implementation science to understand teledermatology during the COVID-19 pandemic |
S. Briggs, J. Lipoff, S. Collier |
| 96 |
[GO] |
2021―Apr―19 |
391 Public sunscreen dispensers and consumer sunscreen trends during the COVID-19 pandemic |
J. Maghfour, C. Rundle, M.D. Szeto, C.L. Presley, C. Eason, C. Dunnick, J. Hugh, R. Dellavalle |
| 97 |
[GO] |
2021―Apr―19 |
281 Racial and language disparities in teledermatology visits for acne during the COVID-19 pandemic |
M.S. Lee, B. Kassamali, N. Shah, A. Lachance, V. Nambudiri |
| 98 |
[GO] |
2021―Apr―19 |
461 A review of cutaneous lymphoma outcomes during COVID-19 pandemic at Columbia University |
T. Garcia-Saleem, C. Stonesifer, L. Geskin |
| 99 |
[GO] |
2021―Apr―19 |
433 Increased risk of hospital acquired sacral pressure injuries in COVID-19 patients |
J. Narang, J. Gallop, S. Seck, A.H. Wei, A.S. Nowacki, A.P. Fernandez |
| 100 |
[GO] |
2021―Apr―19 |
441 Cutaneous findings in COVID-19 patients hospitalized at a large urban academic medical center |
S. Chand, R. Rrapi, J. Lo, C. Gabel, S. Song, Z. Holcomb, C. Iriarte, K. Moore, C. Shi, H. Song, F. Xia, D. Yanes, R. Gandhi, V. Triant, D. Kroshinsky |
| 101 |
[GO] |
2021―Apr―19 |
342 Clinical outcomes in COVID-19 patients with Atopic dermatitis |
H. Pakhchanian, R. Raiker, V.A. Patel |
| 102 |
[GO] |
2021―Apr―19 |
338 Clinical outcomes in COVID-19 patients with dermatopolymyositis |
H. Pakhchanian, R. Raiker, A. Qureshi, V.A. Patel |
| 103 |
[GO] |
2021―Apr―19 |
243 Clinical outcomes in COVID-19 patients with varicella zoster virus |
R. Raiker, H. Pakhchanian, A. Gonzalez Lopez, V.A. Patel |
| 104 |
[GO] |
2021―Apr―19 |
011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients? |
Y. Mitamura, D. Schulz, I. Kolm, S. Oro, M. Levesque, E. Maverakis, C. Akdis, M. Brüggen |
| 105 |
[GO] |
2021―Apr―19 |
254 COVID-19 related outcomes in psoriasis and psoriasis arthritis patients |
R. Raiker, H. Pakhchanian, V.A. Patel |
| 106 |
[GO] |
2021―Apr―19 |
032 A multicomponent skin-targeted COVID-19 vaccine elicits robust humoral and cellular immune responses |
S.C. Balmert, Z.G. Ghozloujeh, C.D. Carey, T.L. Sumpter, G. Erdos, E. Korkmaz, L.D. Falo |
| 107 |
[GO] |
2021―Apr―19 |
381 Perspective of psoriatic disease patients on novel COVID-19 vaccines |
G. Gondo, S. Heydon, S. Bell |
| 108 |
[GO] |
2021―Apr―19 |
205 Evaluation of SARS-CoV-2 spike protein response on PI3K agonist-mediated IL-8 release |
C.E. Borchers, A. Thyagarajan, C. Rapp, J.B. Travers, R. Sahu |
| 109 |
[GO] |
2021―Apr―19 |
332 National trends of dermatology procedures during the COVID pandemic |
R. Raiker, H. Pakhchanian, K. Alam, A. Hakopian, V.A. Patel |
| 110 |
[GO] |
2021―Apr―19 |
335 Trends in dermatological prescribing patterns during the COVID pandemic |
H. Pakhchanian, R. Raiker, K. Alam, A. Hou, V.A. Patel |
| 111 |
[GO] |
2021―Apr―19 |
331 Trends and outcomes in patients with malignant skin cancers during the COVID pandemic |
R. Raiker, H. Pakhchanian, A. Hussain, M. Deng |
| 112 |
[GO] |
2021―Apr―19 |
677 Personal protective equipment needs during the COVID-19 pandemic: A survey of medical dermatologists |
S. Chand, R. Rrapi, C. Gabel, Y. Levin, V. Neel, D. Kroshinsky |
| 113 |
[GO] |
2020―Oct―15 |
ACE2 expression on the keratinocytes and SARS-CoV-2 percutaneous transmission, are they related? |
Ruixuan Zhu, Yaqian Shi, Yixin Tan, Rong Xiao |
| 114 |
[GO] |
2020―Sep―02 |
Clinical research post COVID-19: Embracing a new normal |
Joel M. Gelfand, Brooke E. Hefele |
| 115 |
[GO] |
2020―Aug―14 |
The Impact of Covid-19 on Dermatology Clinical Trials |
Sheena Desai, Priya Manjaly, Karen Lee, Sara J. Li, Cyriac Manjaly, Arash Mostaghimi |
| 116 |
[GO] |
2020―May―23 |
High expression of ACE2 on the keratinocytes reveals skin as a potential target for SARS-CoV-2 |
Xiaotong Xue, Zihao Mi, Zhenzhen Wang, Zheng Pang, Hong Liu, Furen Zhang |
